315 related articles for article (PubMed ID: 33641772)
1. Assessing the Value of Cemiplimab for Adults With Advanced Cutaneous Squamous Cell Carcinoma: A Cost-Effectiveness Analysis.
Konidaris G; Paul E; Kuznik A; Keeping S; Chen CI; Sasane M; Xu Y; Atsou K; Ayers D; Ruiz ES; Khushalani NI; Cope S
Value Health; 2021 Mar; 24(3):377-387. PubMed ID: 33641772
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of cemiplimab vs pembrolizumab for treatment of advanced cutaneous squamous cell carcinoma.
Paul E; Konidaris G; Cope S; Chen CI; Keeping S; Xu Y; Atsou K; Ayers D; Guyot P; Sasane M; Mojebi A; Kuznik A
J Manag Care Spec Pharm; 2021 Nov; 27(11):1513-1525. PubMed ID: 34351214
[No Abstract] [Full Text] [Related]
3. Cost-Effectiveness of Cemiplimab Versus Standard of Care in the United States for First-Line Treatment of Advanced Non-small Cell Lung Cancer With Programmed Death-Ligand 1 Expression ≥50.
Kuznik A; Smare C; Chen CI; Venkatachalam M; Keeping S; Atsou K; Xu Y; Wilson F; Guyot P; Chan K; Glowienka E; Konidaris G
Value Health; 2022 Feb; 25(2):203-214. PubMed ID: 35094793
[TBL] [Abstract][Full Text] [Related]
4. The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United States.
Slater RL; Lai Y; Zhong Y; Li H; Meng Y; Moreno BH; Godwin JL; Frenkl T; Sonpavde GP; Mamtani R
J Med Econ; 2020 Sep; 23(9):967-977. PubMed ID: 32412387
[No Abstract] [Full Text] [Related]
5. Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer.
Aziz MIA; Tan LE; Tan WHG; Toh CK; Loke LPY; Pearce F; Ng K
J Med Econ; 2020 Sep; 23(9):952-960. PubMed ID: 32462958
[No Abstract] [Full Text] [Related]
6. Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden.
Srivastava T; Prabhu VS; Li H; Xu R; Zarabi N; Zhong Y; Pellissier JM; Perini RF; de Wit R; Mamtani R
Eur Urol Oncol; 2020 Oct; 3(5):663-670. PubMed ID: 31412001
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P
Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550
[TBL] [Abstract][Full Text] [Related]
8. Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States.
Huang M; Lou Y; Pellissier J; Burke T; Liu FX; Xu R; Velcheti V
Pharmacoeconomics; 2017 Aug; 35(8):831-844. PubMed ID: 28620848
[TBL] [Abstract][Full Text] [Related]
9. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial.
Migden MR; Khushalani NI; Chang ALS; Lewis KD; Schmults CD; Hernandez-Aya L; Meier F; Schadendorf D; Guminski A; Hauschild A; Wong DJ; Daniels GA; Berking C; Jankovic V; Stankevich E; Booth J; Li S; Weinreich DM; Yancopoulos GD; Lowy I; Fury MG; Rischin D
Lancet Oncol; 2020 Feb; 21(2):294-305. PubMed ID: 31952975
[TBL] [Abstract][Full Text] [Related]
10. Economic evaluation of cemiplimab plus chemotherapy regimen for advanced non-small-cell lung cancer.
Lang Y; Lin Y; Deng M; Liu X
BMC Cancer; 2024 Feb; 24(1):236. PubMed ID: 38383374
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness Analysis of Cemiplimab Versus Chemotherapy as First-Line Treatment in Advanced NSCLC with PD-L1 Expression Levels of at Least 50.
Wang L; Peng Y; Zeng X; Peng L; Li S; Qin S; Wan X; Tan C
Adv Ther; 2021 Aug; 38(8):4354-4365. PubMed ID: 34241780
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab vs Pembrolizumab for Treatment of US Patients With Platinum-Refractory Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Network Meta-analysis and Cost-effectiveness Analysis.
Pei R; Shi Y; Lv S; Dai T; Zhang F; Liu S; Wu B
JAMA Netw Open; 2021 May; 4(5):e218065. PubMed ID: 33956130
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US.
Watson TR; Gao X; Reynolds KL; Kong CY
JAMA Netw Open; 2020 Oct; 3(10):e2016144. PubMed ID: 33052401
[TBL] [Abstract][Full Text] [Related]
14. Cost effectiveness of pembrolizumab vs chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in Switzerland.
Bhadhuri A; Insinga R; Guggisberg P; Panje C; Schwenkglenks M
Swiss Med Wkly; 2019 Dec; 149():w20170. PubMed ID: 31880807
[TBL] [Abstract][Full Text] [Related]
15. Cemiplimab removed from reimbursable drugs in France.
Pham F; Reynaud B; Favier B; Darnis S; Amini-Adle M
Eur J Cancer; 2021 May; 149():11-13. PubMed ID: 33812142
[No Abstract] [Full Text] [Related]
16. Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer.
Sarfaty M; Hall PS; Chan KKW; Virik K; Leshno M; Gordon N; Moore A; Neiman V; Rosenbaum E; Goldstein DA
Eur Urol; 2018 Jul; 74(1):57-62. PubMed ID: 29576265
[TBL] [Abstract][Full Text] [Related]
17. Preliminary Cost-Effectiveness and Cost-Utility Analysis of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma in Italy.
Ghetti G; D'Avella MC; Pradelli L
Clinicoecon Outcomes Res; 2021; 13():121-133. PubMed ID: 33603419
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States.
Bensimon AG; Zhou ZY; Jenkins M; Song Y; Gao W; Signorovitch J; Krepler C; Liu FX; Wang J; Aguiar-Ibáñez R
J Med Econ; 2019 Oct; 22(10):981-993. PubMed ID: 31012765
[No Abstract] [Full Text] [Related]
19. First-line Cemiplimab versus Standard Chemotherapy in Advanced Non-small Cell Lung Cancer Patients with at Least 50% Programmed Cell Death Receptor Ligand-1 Positivity: Analysis of Cost-effectiveness.
Zhang M; Liu X; Wen F; Wu Q; Zhou K; Bai L; Li Q
Clin Oncol (R Coll Radiol); 2022 Mar; 34(3):e123-e129. PubMed ID: 34736841
[TBL] [Abstract][Full Text] [Related]
20. CASE (CemiplimAb-rwlc Survivorship and Epidemiology) study in advanced cutaneous squamous cell carcinoma.
Migden MR; Chandra S; Rabinowits G; Chen CI; Desai J; Seluzhytsky A; Sasane M; Campanelli B; Chen Z; Freeman ML; Ibrahim SF; Khushalani NI; Andria M; Ruiz E
Future Oncol; 2020 Feb; 16(4):11-19. PubMed ID: 31951149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
